SDZNY vs. STVN: Which Stock Offers Better Value?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy STVN?
Source: NASDAQ.COM
Stock Comparison: Sandoz Group AG Sponsored ADR (SDZNY) has a Zacks Rank of #2 (Buy) indicating a strong earnings outlook, while Stevanato Group (STVN) has a Zacks Rank of #3 (Hold), suggesting a weaker position.
Valuation Metrics: SDZNY shows a forward P/E ratio of 22.38 and a PEG ratio of 1.20, indicating better value compared to STVN's forward P/E of 34.66 and PEG ratio of 2.03.
Value Grades: Based on various valuation metrics, SDZNY holds a Value grade of B, while STVN has a Value grade of C, further supporting SDZNY as the superior value option.
Investment Recommendations: Zacks Investment Research highlights SDZNY as a strong investment opportunity, alongside other top stock recommendations with potential for significant returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STVN
Wall Street analysts forecast STVN stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.070
Low
24.00
Averages
27.00
High
30.00
Current: 15.070
Low
24.00
Averages
27.00
High
30.00
About STVN
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stevanato Group Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Stevanato Group reported a 9% increase in total revenue for fiscal 2025 at constant currency, with a 7% rise on a reported basis, highlighting strong demand in the Biopharmaceutical and Diagnostic Solutions (BDS) segment which achieved double-digit growth.
- High-Value Product Performance: Revenue from high-value solutions surged 31% to EUR 171 million, accounting for approximately 49% of total revenue, indicating the company's strengthening competitive position in the high-value syringe market, particularly driven by demand for the Nexa syringe.
- Optimistic Future Outlook: The company projects 2026 revenue between EUR 1.260 billion and EUR 1.290 billion, with the BDS segment expected to grow in the high-single to low-double digits, reflecting confidence in ongoing investments and market demand for high-value products.
- Engineering Segment Challenges: Despite strong performance in high-value solutions, the Engineering segment saw a 23% revenue decline, indicating challenges with longer order intake cycles, prompting management to adopt a cautious stance while emphasizing the need to balance capacity expansion with market demand.
See More
Stevanato (STVN) Q4 2025 Earnings Call Transcript
See More
Stevanato Group Issues Full-Year Guidance for 2026
- 2026 Profit Guidance: Stevanato Group anticipates adjusted earnings per share of €0.59 to €0.63 for fiscal 2026, indicating a positive outlook on profitability and reflecting ongoing growth potential in drug delivery and diagnostic solutions.
- EBITDA Forecast: The company expects adjusted EBITDA to range from €331.8 million to €346.9 million in 2026, a strong profitability indicator that highlights Stevanato's success in optimizing operational efficiency and cost control.
- Revenue Outlook: Stevanato projects revenue between €1.26 billion and €1.29 billion for 2026, representing growth from €1.186 billion in 2025, showcasing the company's positive performance in market demand and product innovation.
- Stock Price Reaction: Stevanato's stock rose by 5.09% to $15.48 in pre-market trading on the New York Stock Exchange, reflecting investor optimism regarding the company's future performance expectations.
See More
Stevanato Group Issues Fiscal 2026 Guidance
- Earnings Highlights: Stevanato Group reported a Q4 non-GAAP EPS of €0.18 with revenue of €346.5 million, reflecting a 4.8% year-over-year growth, indicating the company's stable growth potential in the market.
- Future Outlook: The company expects fiscal 2026 revenue to range between €1.26 billion and €1.29 billion, with adjusted EBITDA projected between €331.8 million and €346.9 million, showcasing management's confidence in future performance.
- Profitability Expectations: Adjusted diluted EPS is anticipated to be between €0.59 and €0.63, reflecting ongoing efforts to control costs and enhance profitability, which may attract more investor interest.
- Market Reaction: Stevanato Group's structural growth remains intact, with analysts confirming a buy rating, indicating market recognition of its future growth potential, which could drive stock price appreciation.
See More
Stevanato Group Reports Strong Q4 and FY 2025 Financial Results
- Significant Revenue Growth: In Q4 2025, Stevanato Group reported a 5% year-over-year increase in total revenue to €346.5 million, with a 10% rise in the Biopharmaceutical and Diagnostic Solutions segment, indicating strong performance in the high-value solutions market.
- High-Value Solutions Contribution: Revenue from high-value solutions surged 31% year-over-year to €171.4 million, representing 49% of total Q4 revenue, demonstrating the company's successful transition and product optimization to meet market demands.
- Margin Improvement: The gross profit margin for Q4 increased to 30.9%, while the operating profit margin remained steady at 20.2%, reflecting ongoing improvements in high-value product mix and production efficiency, thereby enhancing overall profitability.
- Cash Flow and Capital Expenditures: For 2025, Stevanato Group generated €286.1 million in cash flow from operating activities, with capital expenditures totaling €294.9 million, indicating the company's continued investment in expanding production capacity, which is expected to lay the groundwork for future growth.
See More
Stevanato Group Establishes Fiscal 2026 Guidance
- 2025 Fiscal Year Growth: Stevanato Group reported a 7% year-over-year revenue increase to €1.186 billion for fiscal 2025, with gross profit margin rising by 160 basis points to 29.0%, indicating strong performance in the biopharmaceutical sector that is expected to enhance future profitability and market share.
- Strong Q4 Performance: In Q4 2025, revenue grew by 5% to €346.5 million, with high-value solutions accounting for 49% of total revenue, reflecting the company's strengthened competitiveness in the premium market, which is likely to attract more customers and orders.
- Optimistic 2026 Guidance: The company expects revenue for fiscal 2026 to range between €1.26 billion and €1.29 billion, with adjusted EBITDA projected between €331.8 million and €346.9 million, showcasing management's confidence in future growth, particularly in the expanding biopharmaceutical market.
- Cash Flow and Capital Expenditures: As of December 31, 2025, the company had cash and cash equivalents of €130.6 million and net debt of €337.7 million, indicating a solid liquidity position while supporting future strategic investments and operational needs.
See More
Stevanato Group Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Stevanato Group reported a 9% increase in total revenue for fiscal 2025 at constant currency, with a 7% rise on a reported basis, highlighting strong demand in the Biopharmaceutical and Diagnostic Solutions (BDS) segment which achieved double-digit growth.
- High-Value Product Performance: Revenue from high-value solutions surged 31% to EUR 171 million, accounting for approximately 49% of total revenue, indicating the company's strengthening competitive position in the high-value syringe market, particularly driven by demand for the Nexa syringe.
- Optimistic Future Outlook: The company projects 2026 revenue between EUR 1.260 billion and EUR 1.290 billion, with the BDS segment expected to grow in the high-single to low-double digits, reflecting confidence in ongoing investments and market demand for high-value products.
- Engineering Segment Challenges: Despite strong performance in high-value solutions, the Engineering segment saw a 23% revenue decline, indicating challenges with longer order intake cycles, prompting management to adopt a cautious stance while emphasizing the need to balance capacity expansion with market demand.
See More
Stevanato (STVN) Q4 2025 Earnings Call Transcript
See More
Stevanato Group Issues Full-Year Guidance for 2026
- 2026 Profit Guidance: Stevanato Group anticipates adjusted earnings per share of €0.59 to €0.63 for fiscal 2026, indicating a positive outlook on profitability and reflecting ongoing growth potential in drug delivery and diagnostic solutions.
- EBITDA Forecast: The company expects adjusted EBITDA to range from €331.8 million to €346.9 million in 2026, a strong profitability indicator that highlights Stevanato's success in optimizing operational efficiency and cost control.
- Revenue Outlook: Stevanato projects revenue between €1.26 billion and €1.29 billion for 2026, representing growth from €1.186 billion in 2025, showcasing the company's positive performance in market demand and product innovation.
- Stock Price Reaction: Stevanato's stock rose by 5.09% to $15.48 in pre-market trading on the New York Stock Exchange, reflecting investor optimism regarding the company's future performance expectations.
See More
Stevanato Group Issues Fiscal 2026 Guidance
- Earnings Highlights: Stevanato Group reported a Q4 non-GAAP EPS of €0.18 with revenue of €346.5 million, reflecting a 4.8% year-over-year growth, indicating the company's stable growth potential in the market.
- Future Outlook: The company expects fiscal 2026 revenue to range between €1.26 billion and €1.29 billion, with adjusted EBITDA projected between €331.8 million and €346.9 million, showcasing management's confidence in future performance.
- Profitability Expectations: Adjusted diluted EPS is anticipated to be between €0.59 and €0.63, reflecting ongoing efforts to control costs and enhance profitability, which may attract more investor interest.
- Market Reaction: Stevanato Group's structural growth remains intact, with analysts confirming a buy rating, indicating market recognition of its future growth potential, which could drive stock price appreciation.
See More
Stevanato Group Reports Strong Q4 and FY 2025 Financial Results
- Significant Revenue Growth: In Q4 2025, Stevanato Group reported a 5% year-over-year increase in total revenue to €346.5 million, with a 10% rise in the Biopharmaceutical and Diagnostic Solutions segment, indicating strong performance in the high-value solutions market.
- High-Value Solutions Contribution: Revenue from high-value solutions surged 31% year-over-year to €171.4 million, representing 49% of total Q4 revenue, demonstrating the company's successful transition and product optimization to meet market demands.
- Margin Improvement: The gross profit margin for Q4 increased to 30.9%, while the operating profit margin remained steady at 20.2%, reflecting ongoing improvements in high-value product mix and production efficiency, thereby enhancing overall profitability.
- Cash Flow and Capital Expenditures: For 2025, Stevanato Group generated €286.1 million in cash flow from operating activities, with capital expenditures totaling €294.9 million, indicating the company's continued investment in expanding production capacity, which is expected to lay the groundwork for future growth.
See More
Stevanato Group Establishes Fiscal 2026 Guidance
- 2025 Fiscal Year Growth: Stevanato Group reported a 7% year-over-year revenue increase to €1.186 billion for fiscal 2025, with gross profit margin rising by 160 basis points to 29.0%, indicating strong performance in the biopharmaceutical sector that is expected to enhance future profitability and market share.
- Strong Q4 Performance: In Q4 2025, revenue grew by 5% to €346.5 million, with high-value solutions accounting for 49% of total revenue, reflecting the company's strengthened competitiveness in the premium market, which is likely to attract more customers and orders.
- Optimistic 2026 Guidance: The company expects revenue for fiscal 2026 to range between €1.26 billion and €1.29 billion, with adjusted EBITDA projected between €331.8 million and €346.9 million, showcasing management's confidence in future growth, particularly in the expanding biopharmaceutical market.
- Cash Flow and Capital Expenditures: As of December 31, 2025, the company had cash and cash equivalents of €130.6 million and net debt of €337.7 million, indicating a solid liquidity position while supporting future strategic investments and operational needs.
See More
